Tracking survivors long after treatment ends helps inform medical decisions for today’s patients and much more
Jan. 26, 2018
| By Rachel Tompa / Fred Hutch News Service
Every year since its inception in the early 1980s, the Fred Hutch Long-term Follow-up Program sends out a detailed questionnaire to every transplant survivor. The answers to these questions inform a host of research topics on the long-term effects of transplantation, from graft-vs.-host disease to cataracts, from secondary cancers to infertility and sexual dysfunction.
An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.
American Society of Hematology to recognize Dr. Oliver Press for outstanding mentorship
Aug. 24, 2017
The American Society of Hematology, or ASH, announced that Fred Hutch’s Dr. Oliver “Ollie” Press, an internationally known expert in lymphoma and other blood cancers, will receive an award for outstanding mentorship Dec. 10 at the 59th ASH Annual Meeting and Exposition in Atlanta.
Fred Hutchinson Cancer Research Center bioengineer and cancer researcher Dr. Cyrus Ghajar has focused much of his work on what causes breast cancer cells to metastasize. Now, with the help of a new $1 million grant from the W.M. Keck Foundation, Ghajar and his team are hoping to crack open a mystery that has long puzzled scientists in the field: Why do metastatic cells, which can proliferate in many organs, nearly always fail to grow in skeletal muscles, which account for as much as half the body mass of an adult?